{"entity":{"id":"nct06450574","kind":"trial","name":"Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)","aka":["TAUTEM-T1"],"tldr":"A phase 3 trial of capecitabine in colorectal cancer, run by Corporacion Parc Tauli, not yet recruiting.","summary":"Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study) is a phase 3, randomised interventional study registered as NCT06450574 by Corporacion Parc Tauli, with a registry enrolment figure of 106 participants, started 2024-10 and due to reach its primary completion in 2026-10. Interventions recorded: Capecitabine (Xeloda); 50.4 Gy; Transanal Endoscopic Microsurgery (TEM); Transanal Endoscopic Microsurgery. Conditions listed: Rectal Cancer Stage I. Primary outcome: Rectal preservation in T1,N0,M0 rectal cancer; Total mesorectal excision in T1,N0,M0 rectal cancer. Colorectal eligibility wording from the registry: \"* Rectal adenocarcinomas in the biopsy, located at a distance from the anal margin less than or equal to 10 cm measured by rigid rectoscopy at the time of ER\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06450574","url":"https://clinicaltrials.gov/study/NCT06450574"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt"],"targets":[],"drugs":["capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06450574","phase":"3","setting":"Prospective, Controlled and Randomized Phase III Multicentric Study of the Treatment of T1,N0,M0 Rectal Cancer. Neoadjuvant Therapy and Transanal Endoscopic Surgery vs. Transanal Endoscopic Surgery (TAUTEM-T1 Study)","sponsor":"Corporacion Parc Tauli","enrolled":106,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06450574/","neighbours":{"cancer":[{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}